Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $64.42 USD
Change Today +0.42 / 0.66%
Volume 388.7K
PRXL On Other Exchanges
As of 3:50 PM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).

parexel international corp (PRXL) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/23/15 - $72.69
52 Week Low
07/10/14 - $52.08
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

parexel international corp (PRXL) Related Businessweek News

No Related Businessweek News Found

parexel international corp (PRXL) Details

PAREXEL International Corporation, a biopharmaceutical outsourcing services company, provides clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services for pharmaceutical, biotechnology, and medical device industries worldwide. The company operates in three segments: Clinical Research Services (CRS), PAREXEL Consulting Services (PC), and PAREXEL Informatics (PI). The CRS segment offers clinical trials management, observational studies, patient/disease registries and post-marketing surveillance, data management and biostatistics, epidemiology and health economics/outcomes research, clinical logistics, pharmacovigilance, and clinical pharmacology, as well as related medical affairs, patient recruitment, and investigator site services. The PC segment provides technical expertise and advice in various areas, such as drug development, regulatory affairs, product pricing and reimbursement, commercialization and strategic compliance, and good manufacturing practice compliance consulting; and market development, product development, commercialization, and targeted communications services in support of product launch. The PI segment offers information technology solutions comprising ClinPhone randomization and trial supply management solutions, medical imaging services, regulatory information management solutions, platform solutions, clinical trial management system solutions, electronic data capture systems, Web-based portals, systems integration, electronic patient reported outcomes, and patient diary applications. The company was founded in 1983 and is headquartered in Waltham, Massachusetts.

15,560 Employees
Last Reported Date: 08/20/14
Founded in 1983

parexel international corp (PRXL) Top Compensated Officers

Founder, Chairman and Chief Executive Officer
Total Annual Compensation: $883.3K
President and Chief Operating Officer
Total Annual Compensation: $570.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $691.5K
Senior Vice President of Clinical Research Se...
Total Annual Compensation: $496.7K
Executive Vice President
Total Annual Compensation: $430.0K
Compensation as of Fiscal Year 2014.

parexel international corp (PRXL) Key Developments

Parexel Plans to Lay Off 850 Employees Globally

Parexel announced that it plans to lay off 850 employees globally, but did not specify where the cuts would be focused. The company says it now has 17,440 employees in 51 countries. The company calls a ‘Margin Acceleration Program’ designed to increase profits. It coincided with a slight lowering of what the company previously said it would generate in revenues for the quarter and full year ending.

PAREXEL International Corporation Updates Earnings Guidance for the Fourth Quarter and Full Fiscal Year 2015 Ending June 30, 2015 and Provides Earnings Guidance for the Full Year 2016

PAREXEL International Corporation has updated its forward-looking guidance for the fourth quarter and fiscal year 2015 ending June 30, 2015 and provided earnings guidance for the full Fiscal Year 2015. The company expects that approximately $33 to $43 million of these charges will result in future cash expenditures. The impact of the restructuring charge on fourth quarter and full year of 2015 guidance is expected to be approximately $0.27 per diluted share when taking the mid-point of the range. The company expects to achieve annual pre-tax savings as a result of this charge of between $20 to $30 million over the course of fiscal year 2016, which equates to an estimated benefit of between $0.25 to $0.37 per diluted share, and expects to achieve annual pre-tax savings of approximately $50 to $60 million once the Program is fully completed. For the fourth quarter, the company expects to report revenue in the range between $517 million to $533 million against prior guidance in the range of $520 million to $540 million. GAAP EPS is expected to be in the range between $0.50 to $0.58 against prior guidance in the range of $0.65 to $0.81. Non-GAAP EPS is expected to be in the range between $0.70 to $0.78. For the full year 2015, the company expects to report revenue in the range between $2.010 million to $2.026 million against prior guidance in the range of $2.012 million to $2.032 million. GAAP EPS is expected to be in the range between $2.54 to $2.62 against prior guidance in the range of $2.68 to $2.86. Non-GAAP EPS is expected to be in the range between $2.70 to $2.78 against prior guidance in the range of $2.65 to $2.83. For the full year 2016, the company expects to report revenue in the range between $2.160 million to $2.210 million. GAAP EPS is expected to be in the range between $2.97 to $3.33. Non-GAAP EPS is expected to be in the range between $3.02 to $3.38.

PAREXEL International Corporation Launches Next Generation Data-Driven Monitoring Capabilities Within Perceptive MyTrials Data-Driven Monitoring Solution

PAREXEL International Corporation launched next generation risk-based monitoring capabilities, expanding its Perceptive MyTrials Data-Driven Monitoring solution. Data-Driven Monitoring now further enables clients to perform cross-study analysis of quality, risk, and monitoring work effort by combining analytics, reporting and monitoring activity into a single cohesive solution. The enhancements increase a drug developer's ability to demonstrate appropriate oversight and control of site-related risk, quality, and performance while simplifying monitoring governance and execution. The Perceptive MyTrials Data-Driven Monitoring solution uses a unique, algorithmic-based approach to clinical monitoring to determine risk and monitor workload, enabling flexible and scalable decision-making. Developed by PAREXEL Informatics, it is a key component of the Perceptive MyTrials platform, an integrated suite of applications for managing clinical trials.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRXL:US $64.42 USD +0.4163

PRXL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Charles River Laboratories International Inc $70.43 USD +0.06
GFK SE €39.15 EUR -0.482
ICON PLC $67.58 USD +1.43
IMS Health Holdings Inc $30.63 USD +0.13
WuXi PharmaTech Cayman Inc $42.37 USD +0.92
View Industry Companies

Industry Analysis


Industry Average

Valuation PRXL Industry Range
Price/Earnings 23.4x
Price/Sales 1.8x
Price/Book 5.8x
Price/Cash Flow 14.9x
TEV/Sales 1.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PAREXEL INTERNATIONAL CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at